XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.7.0.1

CONCENTRATIONS | 12 Months Ended
--- | ---
Dec. 31, 2016
Risks and Uncertainties [Abstract] |
Concentration Risk Disclosure [Text Block] |
20. | CONCENTRATIONS
Major Customers For the years ended December 31, 2016, 2015, and 2014, approximately 94%, 7%, and 21% of the Company’s revenues were received from two major customers for continued operations. For the years ended December 31, 2016, 2015, and 2014, approximately 96%, 61%, and 38% of the Company’s total revenues were received from another two customers for discontinued operations. Major Suppliers For the years ended December 31, 2016, 2015 and 2014, purchases from three suppliers for continued operations were approximately 98%, 87% and 68% of the total purchase, respectively. For the years ended December 31, 2016, 2015, and 2014, purchases from another three suppliers for discontinued operations were approximately 94%, 83% and 94% of the total purchase, respectively. Revenues For the years ended December 31, 2016, 2015 and 2014, the Company’s top three selling products accounted, in the aggregate, for approximately 97%, 72%, and 74%, respectively, of its total net revenues. The following represents the revenues by product line, all derived from China:
|  | For the years ended |
|  | December 31, |
|  | 2016 |  | 2015 |  | 2014 |
Products Line |  |  |  |  |  |  |  |  |  |
Medical Devices |  | $ | 1,305,372 |  | $ | 1,500,957 |  | $ | 16,000,881 |
Respiratory and Oxygen Homecare |  |  | 5,956 |  |  | 20,573 |  |  | 53,755 |
Mobile Medicine |  |  | 12,080,164 |  |  | 164,503 |  |  | 1,631,413 |
Total Revenues |  |  | 13,391,492 |  |  | 1,686,033 |  |  | 17,686,049 |
Less: revenues from discontinued operations |  |  | (329,119) |  |  | (947,732) |  |  | (14,911,808) |
Revenues from continuing operations |  | $ | 13,062,373 |  | $ | 738,301 |  | $ | 2,774,241 |

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6327-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6442-108592 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration